Treatment Options After CAR T Therapy for Large B-Cell Lymphoma

Video

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

This content originally appeared on our sister site, OncLive.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025

News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025

CGTLive Staff
March 9th 2025
Article

In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest news and expert insights in gene therapy for hemophilia, which is among the most common of these disorders.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

CGTLive Staff
March 6th 2025
Article

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

ImmunoLogic

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
January 31st 2025
Podcast

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

CGTLive Staff
March 2nd 2025
Article

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – February 28, 2025

CGTLive Staff
February 28th 2025
Article

Review top news and interview highlights from the week ending February 28, 2025.

© 2025 MJH Life Sciences

All rights reserved.